News

Filter

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

28-11-2014

Japanese drug major Daiichi Sankyo and Belgian drugmaker UCB have entered into an agreement to jointly…

Daiichi SankyoJapanlacosamide Tablet and InjectionLicensingNeurologicalPharmaceuticalUCBVimpat

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

28-05-2014

Japanese drug majors Dainippon Sumitomo Pharma and Daiichi Sankyo have entered into a license agreement…

ArgentinaBrazilDaiichi SankyoDainippon Sumitomo PharmaLicensinglurasidoneNeurologicalPharmaceuticalSouth AmericaVenezuela

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Daiichi Sankyo US unit buys Roxro Pharma to gain pain drug SPRIX

14-12-2010

Luitpold Pharmaceuticals, a New York, USA-based subsidiary of Japanese drug major Daiichi Sankyo (TKO:…

Daiichi SankyoLuitpold PharmaMergers & AcquisitionsNeurologicalPharmaceuticalRoxro PharmaSPRIX

Portugal’s pharma market expected to grow at compound annual rate of 2.8%

09-11-2009

Business Monitor International calculates that pharmaceutical sales in Portugal reached 3.61 billion…

Daiichi SankyoEuropeGeneralHealthcareMarkets & MarketingNeurologicalPharmaceuticalSankyo

Back to top